In FDA double header, regulators also offer a green light to Rigel's fostamatinib
Fast on the heels of Ultragenyx’s big FDA win, Rigel $RIGL came through with an FDA approval for fostamatinib, a new second-line therapy for thrombocytopenia in adult patients with chronic immune thrombocytopenia. The therapy will be sold as Tavalisse.
The news spread fast on Twitter after the FDA posted the label for the drug, which arrived just days after someone at the company accidentally posted a notice of the OK ahead of the official word.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.